Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Safety Profiles of Polymyxins, Aminoglycosides, and Imipenem/Cilastatin/Relebactam (IMI/REL) in the Treatment of Gram-Negative Infections: A Literature Review
Antibiotics
May 2026
Collings H.
Open Access
An overview of outer membrane protein A (OmpA) as a therapeutic target for Acinetobacter baumannii infection
Expert Opinion on Therapeutic Targets
2026
Islam M.M.
Novel Kidney Biomarkers and Antibiotics-Induced Acute Kidney Injury: A Practical Assessment of Current and Future Applications
Clinical and Translational Science
December 2025
Karimzadeh I.
Open Access
Study progress of novel biomarkers for early prediction of polymyxin-associated acute kidney injury
China Pharmacy
January 2025
Yang G.
Microbiologic cure with a simplified dosage of intravenous colistin in adults: A retrospective cohort study
Infection and Drug Resistance
2023
Al-Zubairy S.A.
Open Access
The potential role of adjunctive ascorbic acid in the prevention of colistin-induced nephrotoxicity in critically ill patients: A retrospective study
Saudi Pharmaceutical Journal
December 2022
Al Sulaiman K.
Open Access
Enhanced antibacterial effect of a novel Friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter baumannii
Scientific Reports
December 2022
Wintachai P.
Open Access
The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
Microbiology Spectrum
September 2022
Wang Y.
Open Access
Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis
Journal of Clinical Medicine
June-1 2022
Huang C.
Open Access
Serum and urinary biomarkers for early detection of acute kidney injury following Hypnale spp. envenoming
Plos Neglected Tropical Diseases
December 2021
Wijewickrama E.S.
Open Access
Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins
Clinical Microbiology and Infection
May 2021
Wagenlehner F.
Open Access
Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis
Journal of Global Antimicrobial Resistance
March 2021
Liu J.
Open Access
Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)
Expert Opinion on Drug Safety
2021
Truong C.B.
Efficacy and safety of colistin loading dose: A meta-analysis
Journal of Antimicrobial Chemotherapy
1 July 2020
Bellos I.
Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: Incidence and clinical outcomes
Nephrology
1 January 2020
Thammathiwat T.
Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): An investigator-driven, open-label, randomized, noninferiority controlled trial
Critical Care
28 November 2019
Cisneros J.M.
Open Access
Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing enterobacteriaceae
Clinical Microbiology Reviews
April 2018
Rodríguez-Baño J.
Open Access